Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial.
published in: PLOS MEDICINE
date of publication: 2017-11-14
language: English
main subject: phase I clinical trial
Cites articles 63
Date
Title
Article - wd:Q44536209